Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia

NCT01162031 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped no accrual

Conditions

Leukemia
Acute Lymphocytic Leukemia

Interventions

DRUG: Velcade

Sponsor

Stanford University

Collaborators

[object Object]